Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2012

View Archived Issues

Pluristem seeks orphan drug designation for PLX cells

U.K. clearance for GenSpera's phase II prostate cancer study

Lorus Therapeutics receives funding to support development of IL-17E

Wista Laboratories presents new tau aggregation inhibitors

New antimalarial agents presented by CSIR

Novartis prepares novel c-Met inhibitors

Novel cathepsin D inhibitors patented by Merck KGaA

Novel rabies virus vectors presented by U.S. Department of HHS

Adenosine-based therapy shows promise for the treatment of priapism

Bristol-Myers Squibb patents new agents for HIV

Novel calcium channel blocker induces analgesia in cancer pain model

Silodosin evaluated for premature ejaculation

to-BBB receives funding to develop treatments for inherited photoreceptor degeneration

BMS discovers novel P2Y1 receptor antagonists with antithrombotic activity

Aerpio Therapeutics completes financing round to support AKB-9778 development

FDA approves higher dose of Exelon Patch for Alzheimer's disease

Valeant Pharmaceuticals to acquire Medicis Pharmaceutical

New series of GPR119 agonists optimized by Bristol-Myers Squibb

Innate Pharma cleared to begin phase II study of IPH-2102 in AML

Genentech describes mTOR inhibitor chosen as development candidate

BioFocus and Ono Pharmaceutical to collaborate on CNS drugs

Agios and UPenn establish new collaboration

Genfit cleared to begin phase IIb NASH study in U.S.

European approval for Pfizer's Inlyta